Silo Pharma issues warrant for up to 300,000 shares in unregistered sale under asset purchase deal

• Silo Pharma entered an asset purchase agreement with Norsight Consulting, issuing an unregistered warrant for up to 300,000 common shares.
• Warrant exercise price set at $1.51 per share, exercisable from April 1, 2027, expiring Sept. 30, 2031.
• Sale relied on Securities Act Section 4(a)(2) exemption for the warrant and underlying shares.
• Ownership cap limits exercise if it lifts Norsight above 4.99% of outstanding stock, adjustable up to 9.99% with notice.
• Lock-up restricts sales of shares received for up to 12 months, unless a change in control or company consent occurs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-106435), on October 02, 2026, and is solely responsible for the information contained therein.